Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris

References

• Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-8
   PubMedGoogle Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
   PubMed Web of Science ®Google Scholar
• Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician 2006;73:636-44
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PCM, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate once or twice daily compared to calcipotriol twice daily in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation Daivobet is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-73
   PubMed Web of Science ®Google Scholar
• Papp K, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007;23:1887-901
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Gibb DM, Ades AE. Validity of indirect comparisons in meta-analysis. Lancet 2007;369:70
   Google Scholar
• Sutton AJ, Abrams KR, Jones DR, et al. Systematic reviews of trials and other studies. Health Technol Assess 1998;2:1-276
   PubMedGoogle Scholar
• Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
   PubMed Web of Science ®Google Scholar
• Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 2006;15:373-81
   PubMed Web of Science ®Google Scholar
• Woolacott N, Bravo V, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:1
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 6-1-2008
   Google Scholar
• PBAC and Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee (PBAC). 9-1-2002
   Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-64
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978;157:238-44
   PubMedGoogle Scholar
• Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5
   PubMed Web of Science ®Google Scholar
• Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005;141:82-4
   PubMed Web of Science ®Google Scholar
• Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006;22:671-81
   PubMed Web of Science ®Google Scholar
• Bourke JF, Iqbal SJ, Hutchinson PE. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol 3 micrograms/g and calcipotriol 50 micrograms/g in the treatment of chronic plaque psoriasis vulgaris. Acta Derm Venereol 1997;77:228-30
   PubMed Web of Science ®Google Scholar
• Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatol Treat 2003;14:8-13
   PubMedGoogle Scholar
• Lahfa M, Mrowietz U, Koenig M, et al. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol 2003;13:261-5
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, van der Valk PG, Swinkels OQ, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006;155:800-7
   PubMed Web of Science ®Google Scholar
• Duweb G, Alhaddar J, Abuhamida M. Psoriasis vulgaris: once- versus twice-daily application of calcipotriol cream. Int J Tissue React 2005;27:155-8
   PubMedGoogle Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomized, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product Daivobet/Dovobet/Taclonex in the treatment of psoriasis vulgaris. Dermatology 2006;213:319-26
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60
   PubMed Web of Science ®Google Scholar
• Perez A, Chen TC, Turner A, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:238-46
   PubMed Web of Science ®Google Scholar
• Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatol Treat 2007;18:361-5
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308-13
   PubMed Web of Science ®Google Scholar
• Berth Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-71
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Berth J, Claudy A, et al. Comparative study of calcipotriol MC 903 ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-43
   PubMed Web of Science ®Google Scholar
• Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol MC 903 ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992;27:983-8
   PubMed Web of Science ®Google Scholar
• Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000;201:139-45
   PubMed Web of Science ®Google Scholar
• Kragballe K, Gjertsen BT, de Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6
   PubMed Web of Science ®Google Scholar
• Kragballe K, Barnes L, Hamberg K, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649-54
   PubMed Web of Science ®Google Scholar
• Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol MC903 cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis: a randomized, double-blind, parallel group multicentre study Calcipotriol Study Group. Br J Dermatol 1997;136:89-93
   PubMed Web of Science ®Google Scholar
• Monastirli A, Zografakis C, Braun H, et al. Calcipotriol vs. Anthralin in the treatment of chronic plaque psoriasis. Z Hautk 2000;75:626-9
   Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomized, double-blind trial. Dermatology 2004;209:308-13
   PubMed Web of Science ®Google Scholar
• Salmhofer W, Maier H, Soyer HP, et al. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl 2000;5-8
   PubMedGoogle Scholar
• Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673-7
   PubMed Web of Science ®Google Scholar
• Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai 2007;90:1997-2002
   PubMedGoogle Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li W, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-7
   PubMed Web of Science ®Google Scholar
• Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther 1998;20:851-69
   PubMed Web of Science ®Google Scholar
• British Association of Dermatologists. Guidelines for psoriasis. 1-1-2006
   Google Scholar
• Poulin Y. Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis. Skin Ther Lett 2002;7:1-3
   PubMedGoogle Scholar
• Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-14
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet(R)/Dovobet(R)) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151:663-8
   PubMed Web of Science ®Google Scholar